Literature DB >> 6842492

Bioavailability and pharmacokinetics of D-penicillamine.

W R Kukovetz, E Beubler, F Kreuzig, A J Moritz, G Nirnberger, L Werner-Breitenecker.   

Abstract

The absolute and the relative bioavailability of D-penicillamine, available from different dosage forms and products, was studied in 10 healthy volunteers. Plasma levels and urine excretion of D-penicillamine were determined up to 8 h after administration by high performance liquid chromatography after intravenous administration of 250 mg and after oral administration of 250 mg (2 products) and 150 mg (1 product) D-penicillamine. The absolute bioavailability on oral administration was 50-70%. No statistical difference was found between the relative bioavailabilities of the different dosage forms tested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842492

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

2.  Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.

Authors:  T Matsubara; R Saura; K Hirohata; M Ziff
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

Review 3.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

4.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.

Authors:  D A Joyce; R O Day
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 6.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 7.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 8.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 9.  Chelation therapy in liver diseases of childhood: Current status and response.

Authors:  Jayendra Seetharaman; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.